Recombinant Mouse SPARC-like 1/SPARCL1 Protein, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse SPARC-like 1/SPARCL1 Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit the cell growth of Mv1Lu mink lung epithelial cells. Schiemann, B.J. et al. (2003) Mol. Biol. Cell. 14:3977. The ED₅₀ for this effect is 0.5-2.0 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse SPARC-like 1/SPARCL1 protein
  Ile17-Phe650, with a C-terminal 10-His tag
• Accession #: P70663
• N-terminal Sequence: Ile17
• Protein/Peptide Type: Recombinant Proteins
• Gene: Sparcl1
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 72.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 110-140 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse SPARC-like 1/SPARCL1 Protein, CF

• Hevin
• High endothelial venule protein
• MAST 9
• MAST9
• PIG33
• proliferation-inducing protein 33
• SC1
• SPARC like 1
• SPARCL1
• SPARC-like 1 (hevin)
• SPARC-like 1 (mast9, hevin)
• SPARC-like 1
• SPARC-like protein 1

Background

SPARCL1 (Secreted Protein, Acidic and Rich in Cysteines-like 1), also known as hevin, SC1 or MAST9, is a member of the SPARC family of extracellular glycoproteins (1, 2). SPARCL1 is an anti-adhesive protein that is widely expressed in tissues such as brain, heart, lung, muscle and kidney, but not liver (3, 4). Mouse SPARCL1 contains a 16 amino acid (aa) signal sequence and a 634 aa mature region that contains four domains: a 403 aa N-terminal acidic region, a 23 aa
follistatin-like domain, a 55 aa kazal-like segment and a 148 aa calcium binding domain that contains two EF hand motifs (3, 4). Mouse mature SPARCL1 shares 89%, 67%, 63%, 61%, 60% and 58% aa identity with rat, human, equine, canine, porcine and bovine SPARCL1, respectively. The follistatin-like, kazal-like and
calcium-binding domains of SPARCL1 show 61% aa identity with corresponding regions of SPARC. SPARCL1 is predicted at 75 kDa, but migrates at ~130 kDa, which has been explained either by disulfide-linked homodimerization or by glycosylation and high acidity (3 - 5). Some truncated forms have been reported. In mouse, a 55 kDa C-terminal fragment is the only form in kidney and represent a portion of SPARCL1 in other tissues (6). In humans, a 25 kDa form is increased in liver tumors that are encapsulated, while the full-length form is down-regulated in many epithelial cell-derived tumors (7, 8). SPARCL1 inhibits adhesion and spreading on a variety of substrates (5, 9). It is thought to cause antiadhesive signaling that terminates neuronal migration, consistent with production by glial and neuronal cells during development or in response to trauma (10). In tonsillar high endothelial venules (HEV), SPARCL1 may induce endothelial cell dissociation, promoting extravasation (3). SPARCL1 binds collagen; in mice, deletion causes dermal collagen fibrils that are smaller in diameter and deficient in decorin (6, 11).

1. Framson, P. E. and E. H. Sage (2004) J. Cell. Biochem. 92:679.
2. Sullivan, M. M. and E. H. Sage (2004) Int. J. Biochem. Cell Biol. 36:991.
3. Girard, J. P. and T. A. Springer (1995) Immunity 2:113.
4. Bendik, I. et al. (1998) Cancer Res. 58:626.
5. Brekken, R. A. et al. (2004) J. Histochem. Cytochem. 52:735.
6. Hambrock, H. O. et al. (2003) J. Biol. Chem. 278:11351.
7. Lau, C. P. et al. (2006) J. Pathol. 210:469.
8. Isler, S. G. et al. (2001) Int. J. Oncol. 18:521.
9. Girard, J. P. and T. A. Springer (1996) J. Biol. Chem. 271:4511.
10. Gongidi, V. et al. (2004) Neuron 41:57.
11. Sullivan, M. M. et al. (2006) J. Biol. Chem. 281:27621.

Publications for SPARC-like 1/SPARCL1 (4547-SL)(1)

Publication using 4547-SL

• G Chen, J Xu, H Luo, X Luo, SK Singh, JJ Ramirez, ML James, JP Mathew, M Berger, C Eroglu, RR Ji Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling JCI Insight, 2022-12-08;7(23):. 2022-12-08 [PMID: 36256481] (In Vivo, Mouse)

Bioinformatics

• Gene Symbol: Sparcl1
• Uniprot:
  • P70663()